RedHill Biopharma Ltd. Appoints Dan Suesskind to its Board of Directors
2/22/2011 8:25:51 AM
TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE: RDHL), an Israeli biopharmaceutical company focusing primarily on development of late clinical-stage new formulations of existing drugs, announced today the appointment of Dan Suesskind to the Company's Board of Directors. Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NASDAQ: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind is a member of Teva's board of directors.